reference standard raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-12 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
CE capillary is coupled directly to an electrospray ionization source with a sheathless interface system. The electric contact for ESI is realized by using capillary coated with conductive metal. Because no sheath liquid is used, the system has high sensitivity, low flow rates and minimum background. However, these interface designs, all have challenges including low mechanical robustness, poor reproducibility. The latest sheathless interface design features porous ESI emitter through chemical etching. This design effectively provides robust interfacing with mass spectrometry and addresses the reproducibility challenges associated with previous designs. This porous emitter interface has been explored to couple of CITP/CZE (or transient ITP) which greatly improves sample loading capacity of CE and enabled ultrasensitive detection of trace analytes. High reproducibility, robustness and sensitivity were achieved in sheathless transient capillary isatochophoresis (CITP)/capillary zone electrophoresis (CZE) -MS interface, where conductive liquid was used. Conductive liquid contacts with the metal-coated outer surface of the emitter completing the circuit, but at the same time it does not mix with separation liquid and therefore there is no sample dilution.
== Medical uses == Metenolone, as its esters, is used almost exclusively in the treatment of anemia due to bone marrow failure. It has also been used to treat wasting syndromes due to major surgery, infection, long-term corticosteroid therapy, malnutrition, or other causes. It has also been used to treat osteoporosis and sarcopenia, to inhibit the natural loss of muscle mass with aging, and to promote weight gain in underweight premature infants and children.
=== Cholesterol control === There is inconsistent evidence regarding the effect of LDL-cholesterol levels on stroke risk after TIA. Elevated cholesterol may increase ischemic stroke risk while decreasing the risk of hemorrhagic stroke. While its role in stroke prevention is unclear, statin therapy has been shown to reduce all-cause mortality and may be recommended after TIA.
== Mobile phases == A mobile phase in RP-LC consists of mixtures of water or aqueous buffers, to which further solvents are added, to elute analytes from a reversed-phase column in a selective manner. The added solvents must be miscible with water. These are also called "modifiers", since they modify the polarity of the mobile phase. Water is the most polar solvent in the reversed phase mobile phase. To increase the elution strength of the mobile phase, one usually add modifiers to lower its polarity. Common modifiers include acetonitrile (ACN), methanol (MeOH), 2-propanol (isopropanol, IPA), ethanol (EtOH) and tetrahydrofuran (THF).
Sources: en.wikipedia.org
== Protein synthesis == Protein anabolism is the process by which proteins are formed from amino acids. It relies on five processes: amino acid synthesis, transcription, translation, post translational modifications, and protein folding. Proteins are made from amino acids. In humans, some amino acids can be synthesized using already existing intermediates. These amino acids are known as non-essential amino acids. Essential amino acids require intermediates not present in the human body. These intermediates must be ingested, mostly from eating other organisms.
=== Pharmacodynamics === Oxymorphone elicits its effects by binding to and activating the μ-opioid receptor (MOR) and, to a much lesser extent, the δ-opioid receptor (DOR) and κ-opioid receptor (KOR). Its activity at the DOR may augment its action at the MOR. Oxymorphone is 10 times more potent than morphine. 1.02 mg of oxymorphone hydrochloride produces analgesia roughly equivalent to 10 mg of morphine sulfate, with similar peak and duration of effect but potentially slightly fewer side effects at equipotent doses.
=== South Africa === Saudi Arabia supplies most of South Africa's fuel. The South African Government has said that there was no shortage of fuel in the country, but prices have increased and some petrol stations have introduced their own rationing of diesel. With more traffic potentially taking the route around the Cape of Good Hope, and ships needing to fuel along the African coast, some ports such as Walvis Bay, Cape Town, and Durban may come under increased pressure, but also benefit from the diversion.
On 18 January, ambassadors from all 27 member states of the EU held an emergency meeting on Trump's threats. After Trump reversed his decision on implementing tariffs, EU officials were sceptical, but announced on 22 January that approval of the trade agreement would resume.
=== HIV infection === Macrophages also play a role in human immunodeficiency virus (HIV) infection. Like T cells, macrophages can be infected with HIV, and even become a reservoir of ongoing virus replication throughout the body. HIV can enter the macrophage through binding of gp120 to CD4 and second membrane receptor, CCR5 (a chemokine receptor). Both circulating monocytes and macrophages serve as a reservoir for the virus. Macrophages are better able to resist infection by HIV-1 than CD4+ T cells, although susceptibility to HIV infection differs among macrophage subtypes.
Sources: en.wikipedia.org
creatine + phosphate Thus, the two substrates of this enzyme are N-phosphocreatine and H2O, whereas its two products are creatine and phosphate. This enzyme belongs to the family of hydrolases, specifically those acting on phosphorus-nitrogen bonds. The systematic name of this enzyme class is phosphamide hydrolase. This enzyme is also called creatine phosphatase.
== Description == There is no mention of the Korean People's Revolutionary Army in documents written by Kim Il Sung himself during his time in the Soviet Army. Coined in the wake of the May 25th Instructions, the purported army is connected to Kim Il Sung's cult of personality initiated by the guerrilla faction from the Soviet Army's 88th Separate Rifle Brigade, which seized power in North Korea. The KPRA was first mentioned in the late 1940s. Korean People's Revolutionary Army was allegedly founded on 25 April 1932. North Korean historiography credits the defeat of Japan in 1945 mostly to the KPRA, downplaying Soviet involvement. From 1978, North Korea marked 25 April as the "true" founding date of the Korean People's Army (KPA), with the KPA being claimed to just be the reconstitution of the KPRA. North Korean leader Kim Jong Un moved back the KPA's official founding date back to its original date of 8 February 1948, with 25 April instead becoming the official foundation date of the KPRA
Suborder † Ceratitina Suborder † Phylloceratina Suborder † Lytoceratina Suborder † Ammonitina Subsequent revisions include the establishment of three Upper Cambrian orders, the Plectronocerida, Protactinocerida, and Yanhecerida; separation of the pseudorthocerids as the Pseudorthocerida, and elevating orthoceratid as the Subclass Orthoceratoidea.
Byzantine territories fragmented into competing political entities. The crusaders crowned Baldwin I as the ruler of a new Latin Empire in Constantinople; it soon suffered a crushing defeat against the Bulgarians in 1205. It also failed to expand west or east, where three successor states had formed: the Empire of Nicaea and the Empire of Trebizond in Asia Minor, and the Despotate of Epirus on the Adriatic. The Venetians acquired many ports and islands, and the Principality of Achaea emerged in southern Greece. Trebizond lost the key port of Sinope in 1214 and thereafter played little role away from the southeastern Black Sea. For a time, Epirus appeared well placed to reclaim Constantinople from the Latins, and its ruler Theodore Doukas crowned himself emperor, but he suffered a critical defeat at the Battle of Klokotnitsa in 1230, and Epirote power waned. Nicaea, ruled by the Laskarid dynasty and drawing on both Byzantine refugees and local populations, blocked the Latins and the Seljuks of Rum from expanding east and west respectively. John III (r. 1221–1254) strengthened Nicaea militarily, economically, and diplomatically. He discouraged imports and promoted local production, and he made many diplomatic treaties, especially after Mongol armies ravaged Bulgaria and defeated Rum between 1237 and 1243. This chaos was an opportunity for John, and he fought many successful campaigns against the states disrupted by the Mongol invasions. Soon after his death, his grandson was usurped by Michael VIII, founder of the Palaiologos dynasty, who recaptured Constantinople in 1261.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.